

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number  
**WO 02/088331 A1**


- (51) International Patent Classification<sup>7</sup>: C12N 5/06, (74) Agent: ROBIC; 55 St-Jacques, Montréal, Québec H2Y 3X2 (CA).  
A61L 27/00, A61F 2/02, C08L 29/04
- (21) International Application Number: PCT/CA02/00652
- (22) International Filing Date: 1 May 2002 (01.05.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/287,370 1 May 2001 (01.05.2001) US
- (71) Applicant: UNIVERSITE DU QUEBEC A MONTREAL [CA/CA]; Succursale Centre-Ville, Case Postale 8888, Montréal, Québec H3C 3P8 (CA).
- (72) Inventors: DENIZEAU, Francine; 599 rue de la Savoyane, Iles des Soeurs, Verdun, Québec H3E 1Y7 (CA).  
MATEESCU, Mircea-Alexandru; 377 rue Sherbrooke West, Apt. 505, Montréal, Québec H3A 1B5 (CA).  
LUNA SAAVEDRA, Yàscara, Grisel; 9030 rue Verdille, Montréal, Québec H2N 1Y3 (CA).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations*

[Continued on next page]

(54) Title: TRIDIMENSIONAL BIOCOMPATIBLE SUPPORT STRUCTURE FOR BIOARTIFICIAL ORGANS AND USES THEREOF



(57) Abstract: The present invention relates to a biocompatible support structure for culturing cells in three dimensions. In a preferred embodiment, the support structure is constituted essentially of cross-linked polyvinylalcohol (PVA). More preferably, the matrix has the form of a sponge and is used for the culture of hepatocytes. The invention also relates to methods of manufacturing such structure and to methods of using the same *in vitro*, *ex vivo* as well as *in vivo*. The invention further relates to a bioartificial organ and to a tridimensional cell culture system which may be used for the production of therapeutic proteins, used as a detoxification device, used as a tool in predictive toxicology of compounds in the pharmaceutical industry and/or used for transplantation.

WO 02/088331 A1



- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

## TRIDIMENSIONAL BIOCOMPATIBLE SUPPORT STRUCTURE FOR BIOARTIFICIAL ORGANS AND USES THEREOF

### RELATED APPLICATION

5 This application claims priority of United States Provisional Application 60/287,370 filed May 1<sup>st</sup>, 2001, the disclosure of which is incorporated by reference herein in its entirety.

### BACKGROUND OF THE INVENTION

#### 10 A) Field of the invention

The present invention relates to a biocompatible support structure for culturing cells in three dimensions. The invention also relates to methods of manufacturing such structure and to methods of using the same *in vitro*, *ex vivo* as well as *in vivo*, particularly as a bioartificial organ.

15

#### B) Brief description of the prior art

Over the last decade, there has been a continuously growing interest in new polymeric matrices for growing cells and tissues. However, despite the multitude of polymeric matrices that have been developed (e.g. hydrogels, hydrophilic or hydrophobic matrices), the mechanical characteristics and compatibility with the cultured tissues must still be improved. In this context, special attention was paid to hydrogels and sponges based on polymeric materials, which are already accepted in various therapeutic applications. They consist of hydrophilic macromolecules cross-linked to form a swellable but insoluble three-dimensional network. As examples, such hydrophilic polymers include hydroxypropyl-methylcellulose [HPMC], ethylcellulose, acyl-substituted cellulose and vinylic polymers such as poly(hydroxyethylmethacrylate)-PHEMA, polyacrylamides, other acrylic copolymers, polyvinylacetate (PVAc), polyvinylpyrrolidone (PVP), polyesters, and many other derivatives that are used as pharmaceutical excipients. Polymer swelling and the permeability of solutes (i.e., metabolites) through hydrogels depend on the chemical structure of the polymer (composition, molecular weight, cross-linking density and crystallinity as

20  
25  
30

well as on the type of the agent to be transferred), which can modulate the viability of the system.

Various substrata have been used for the culture of hepatocytes *in vitro* based upon natural as well as synthetic materials. Natural materials such as laminin, fibronectin, entactin, collagen, perlecan, glycoproteins, proteoglycans and MATRIGEL® have the advantage of being capable of specific interactions with the cells, but their availability is extremely limited and their costs very high, making them inapplicable when large quantities are needed. Other natural polymers such as alginates do not have the same limitations. However, they lack motifs for specific interactions with the cells, and their properties cannot be easily modified to compensate for this severe drawback.

Synthetic materials have been shown to be useful for controlled drug release tablets. For instance, US patent No. 5,456,921 describes the use of cross-linked amylose as a matrix for the slow release of biologically active compounds. Similarly, interpenetrated CL-HAS and CL-PVA networks CL (HAS-PVA) have been produced and used as excipients for controlled drug release tablets (U.S. patent No 6,284,273).

Synthetic materials have also been shown to be useful for *in vitro* cell culture, including: polyhydroxymethylmetacrylate, poly-L-lactic acid, polyglycolic acid, poly-N-p-vinylbenzyl-d-lactonamide, polycaprolactone, cross-linked polyurethane, polyvinylformal and polyvinylalcohol. These polymers offer interesting advantages because they can be synthesized in large quantities in a reproducible manner and at low cost. Moreover, their mechanical and chemical properties can be modified and improved, so that they are enriched in specific information providing optimal cell signaling and performance.

Despite the efforts that have been devoted so far to the development of a bioartificial organ such as bioartificial liver, the existing models all suffer from important limitations. They all show a lack of performance regarding at least one of the key features in optimal system design, which include: the tridimensional structure of the substratum, the availability and cost of the tridimensional substratum, the potential for enriching the tridimensional substratum in specific

information for cell anchorage and programmed signaling, and the ease of perfusion of the cell-substratum phase.

There is thus a need a tridimensional culture system that circumvents the above-mentioned limitations.

5        There is also a need for a biocompatible support structure for culturing cells and growing tissues in three dimensions and which offers improved mechanical properties, better biocompatibility with cultured cells and tissues, and a higher stability against enzymatic or microbial degradation.

10       There is further a long felt need for bioartificial organs such as a bioartificial liver.

There is a need also for improved *ex vivo* methods for producing therapeutic proteins, for the detoxification of body fluids, and for evaluating the toxicity and biological activity of compounds in the pharmaceutical industry.

15       The present invention fulfils these needs and also other needs which will be apparent to those skilled in the art upon reading the following specification.

### SUMMARY OF THE INVENTION

20       An object of the invention is to provide a support structure that can be used as a matrix for cell and tissue growing, and which offers improved mechanical properties, better biocompatibility with cultured cells and tissues, and a higher stability against enzymatic or microbial degradation than existing cell culture systems.

25       Therefore, according to two related aspects, the invention relates to a biocompatible support structure for culturing cells in three dimensions and to bioartificial organs that mimic the *in vivo* microenvironment of chosen cells. In a preferred embodiment, the support structure is constituted essentially of cross-linked polyvinylalcohol (PVA). More preferably, the matrix has the form of a sponge and is used for the culture of hepatocytes. In another preferred embodiment, the bioartificial organ is a bioartificial liver which allows physiological  
30       exchanges between the cells constituting the same and extracellular fluid.

According to another aspect, the invention relates to a practical, efficient and economic tridimensional cell culture system for the culture of mammalian

cells, and more particularly human hepatocytes, that solves several problems that could not be solved by the conventional monolayer culture such as loss of liver-specific functions, dedifferentiation and cell mortality.

5 The bioartificial organs and culture system of the invention may be used for the production of therapeutic proteins, used as a detoxification device, used as a tool in predictive toxicology of compounds in the pharmaceutical industry and/or used for transplantation.

10 An advantage of the present invention is that it provides a tridimensional support structure for cell culture that is easy to manipulate, that is biocompatible, non-biodegradable and which shows stable mechanical and chemical properties *in vitro* as well as *in vivo*. The support structure of the invention further comprises interconnected channels that allow cell-cell communication, a very important feature for cell survival. It is also possible to modify the polymeric matrix and/or to incorporate thereto bioactive molecules in order to improve cell-matrix  
15 interactions, cell-cell interactions and matrix-recipient interactions.

According to one aspect, the invention relates to a tridimensional cell culture system in which the cells remain viable and are capable of maintaining a number of specific functions over a long period of time, for instance albumin secretion for liver cells.

20 Other objects and advantages of the present invention will be apparent upon reading the following non-restrictive description of several preferred embodiments, made with reference to the accompanying drawings.

## BRIEF DESCRIPTION OF THE DRAWINGS

25

Figures 1A and 1B are confocal microscopy images of hepatocytes adhering to the support structure of the invention after 72 hours of culture. Fig. 1A: General view of a preferred embodiment (highly porous PVA matrix) showing interconnected pores (bar = 500  $\mu$ m). Fig. 1B:  
30 Hepatocytes (green) are shown making cell-cell and cell-matrix interactions (bar = 100  $\mu$ m). Propidium iodide was used as a red marker

for the PVA matrix and 5-chloromethylfluorescein diacetate as a green marker for live hepatocytes.

5 **Figure 2** is a diagram showing a preferred embodiment of a tridimensional culture system according to the present invention.

10 **Figure 3** is a graph showing the percentage of hepatocytes adherent to different types of support structures under static culture conditions. Abbreviations: M: disc of PVA-matrix unmodified; MM: disc on PVA-matrix modified by aminoethylation both being tridimensional static cultures; and F: collagen film in monolayer culture.

15 **Figure 4** is a graph showing the percentage of lactate dehydrogenase released over time by hepatocytes cultured on different supports and under static culture conditions. The abbreviations are the same as in Figure 3.

20 **Figure 5** is a graph showing the adherence of hepatocytes on different supports and under dynamic culture conditions. Abbreviations: cM: cylinder-shaped PVA polymer-matrix without any modification; cMM: cylinder-shaped PVA polymer-matrix modified with aminoethylation, both being tridimensional supports under dynamic culture conditions; and F: collagen film in monolayer culture as control.

25 **Figure 6** is a graph showing the percentage of lactate dehydrogenase released by hepatocytes cultured on different supports and under dynamic culture conditions. The abbreviations are the same as in Figure 5.

### DETAILED DESCRIPTION OF THE INVENTION

30 The present invention relates to a biocompatible support structure for culturing cells in three dimensions, consisting essentially of a biocompatible and non-biodegradable polymeric material on which cells may adhere and proliferate.

As used herein, "biocompatible" means compatible and relatively favorable to cell attachment and proliferation, and without overly negative effects onto these two cell-related functions. As used herein, "non-biodegradable" means substantially resistant to chemical degradation or enzymatic digestion which occurs normally in biological systems. For the purposes of the present invention, resistance to chemical degradation or enzymatic digestion is long enough so that the support structure performs its desired function(s) (typically a few days), but it may be longer (weeks, months, years).

The invention also relates to methods of manufacturing such a biocompatible structure and to methods of using the same *in vitro*, *ex vivo* as well as *in vivo*, particularly as a bioartificial organ.

Preferred cells to be cultured on the support structure of the invention are mammalian cells and more preferably human cells. Preferred cells include but are not limited to hepatocytes, cardiomyocytes, fibroblasts, osteoblasts, cancer cells, monoclonal cells, kidney cells, and pancreatic cells such as Langerhans cells and acinar cells. However, other types of cells could also be used depending on a user's intended uses. Indeed, the origin of the cells can be diverse depending on the application sought (cell line, cells purified from a patient, cells that have been genetically modified, etc).

#### **A) Tridimensional support structure**

According to a first aspect, the invention relates to a biocompatible support structure (also called herein a matrix) for culturing cells in three dimensions. In a preferred embodiment, the support structure consists essentially of a biocompatible and non-biodegradable polymeric material on which cells may adhere and proliferate (see Figures 1A and 1B). The support structure forms, when saturated in a suitable aqueous medium, a porous tridimensional sponge-like scaffold with a plurality of interconnected pores that are dimensioned and distributed so that a flow of at least  $0.1 \text{ ml/min}^{-1}\text{cm}^{-2}$ , preferably  $0.5 \text{ ml/min}^{-1}\text{cm}^{-2}$ , and more preferably of 1 to about  $15 \text{ ml/min}^{-1}\text{cm}^{-2}$ , of an aqueous solution may circulate through the biocompatible support structure. In preferred embodiments,



the support structure comprises from about 20 to about 37 pores/cm<sup>2</sup> and the pores have a diameter of about 100 to about 1000  $\mu$ m.

More preferably, the biocompatible and non-biodegradable polymeric material of which is made the support structure is selected from the group consisting of polyvinylalcohol (PVA), polyuretans, polycyanoacrylates, polyhydroxyethyl methacrylate (PHEMA), methylmethacrylate (MMA), and N-vinyl pyrrolidone (N-VP). Even more preferably, these compounds are treated with cross-linking agents like epichlorohydrin, sodium trimetaphosphate, POCl<sub>3</sub>, formaldehyde (HCHO) and 2,3 dibromophenol.

In a most preferred embodiment, the biocompatible support structure consists essentially of a polyhydroxylic polymer with alternate polar and non-polar groups. More preferably, the support structure consists essentially of cross-linked polyvinylalcohol (PVA) molecules, including but not limited to amino-ethyl-polyvinylalcohol (AE-PVA), arginyl-glycyl-aspartyl-polyvinylalcohol (RGD-PVA) and derivatives thereof.

PVA is a material that possesses interesting characteristics that can be exploited for tridimensional cell culture. The present inventors have found that a PVA-derived support structure according to the present invention exhibits better mechanical properties and improved biocompatibility, when compared with matrices made of other polymers used in prior art. The modified polymeric PVA chains preserve their tridimensional structure over a long period, since PVA is articulated by: a) multipoint interchain covalent bridges introduced by a cross-linking reaction, and b) by interchain hydrogen bonding contributing to network stabilization.

PVA is a polyhydroxylic polymer containing alternate polar (-CH-OH) and non-polar (-CH<sub>2</sub>-) groups. This represents a well-balanced structure in terms of chain polarity, and at the same time, enough flexibility for interchain interactions and particular macromolecular conformations. Based on its crystallinity, a helical structure was assumed for PVA. It appears that a syndiotactic configuration favors both interchain hydrogen association and helical structure. Consequently, this conformation can lead to a higher water-resistance of PVA.

PVA also exhibits fewer polar (-OH) groups per repetitive unit  $-\text{[CH}_2\text{-CH(OH)-]}_n-$ , than carbohydrates. With a hydrophobic -CH<sub>2</sub>- residue, which gives a relative flexibility of the rotation towards the whole polymeric chain, in alternating with the hydroxylic one [-CH(OH-)], which is hydrophilic and can be involved in hydrogen associations, PVA can generate particular helix structures. Cross-linked PVA (CLPVA) can also generate a crystalline network. The tendency to reach an advanced order (interchain stabilization by hydrogen bonding) is a common structural characteristic for several carbohydrates (amylose, agarose) and PVA polymers which are susceptible to form helices. This characteristic is important for network formation. Their reticulation and derivatization can be perfectly compatible with stable structures and adequate properties.

The present inventors also observed that, biocompatible and non-biodegradable polymeric materials comprising an amine function demonstrated an increased adherence of hepatocytes on their surfaces. Therefore, according to a preferred embodiment of the invention, cell attachment capabilities of the support structure are increased by adding amine functions (or related peptides ensuring better cell adhesion) on the surface of the biocompatible and non-biodegradable polymeric material. This can be achieved by modifying the biocompatible and non-biodegradable polymeric material (preferably PVA) with haloalkyl amines. A non-restrictive list of suitable haloalkyl amines includes 2-chloroethylamine hydrochloride, chloropropyl amine, bromoethylamine, iodoethylamine. More preferably, 2-chloroethylamine hydrochloride is used.

The biocompatible support structure of the invention may further comprises an associated polymer incorporated to the structure in order to enhance its possibilities. The associated polymer(s) may constitute from about 1 to about 50 % w/w of the structure and it is selected according to its compatibility with the biocompatible and non-biodegradable polymeric material and according to its usefulness in cell culture. For instance, if the support structure is to be used *ex vivo* in a bioartificial organ such as a prosthesis, it would be preferable that the polymeric material(s) incorporated to the structure be biocompatible, but not

easily biodegradable. For *in vivo* transplantation uses, it would be preferable that the associated polymer(s) incorporated into the structure be biodegradable. A non-restrictive list of suitable associated polymers includes polyethyleneglycol (PEG), agarose, starch, alginate, and chitosan.

5 As it will be explained with more details hereinafter, the biocompatible support structure may also further comprises a bioactive molecule in order to increase the cells attachment and/or cells proliferating capabilities of the structure.

10 In view of the above, one can see that the highly porous and biocompatible support structure of the invention presents numerous beneficial characteristics. Indeed, when saturated in aqueous medium, the support structure preferably takes the form of a porous tridimensional structure similar to that of marine sponges with interconnected pores that are of comparable size and of variable forms. The support structure has a swelling volume that is very flexible and it has  
15 a high mechanical resistance. It is thus capable of resisting to temperatures up to 90°C without showing any plastic deformation. The support structure of the invention may also resists against the action of diluted acids, strong alkali, solutions of common detergents, and most organic solvents.

## 20 **B) Manufacture of the tridimensional support structure**

The support structure of the invention is preferably synthesized according to the specific needs of a user. Although PVA is a highly preferred biocompatible and non-biodegradable polymeric material according to the invention, the present invention is not limited only to PVA-derived matrices. Indeed, PVA is a prototype  
25 polymer with regards to the applications that are described herein. The concept of the invention applies to other polymers sharing with PVA one of many desired properties such as biocompatibility, the capacity to form a porous structure with interconnected pores of controlled dimension; the presence of anchoring groups on the polymer, such as hydroxyl groups, that can serve to add specific biological  
30 functions. The biocompatible and non-biodegradable polymeric material is selected according to a desired use and desired characteristic properties of the

final product. A non-exhaustive list of polymers that fulfills at least some of the previous requirements has been given hereinbefore.

Interestingly, it was found that a PVA-polymeric sponge bought from PVA Unlimited Company (Warsaw, Indiana, USA) possessed most of the above mentioned desired characteristics. Such sponge may be cut out according to a desired shape and use (preferably in the form of a cylinder having a diameter of about 1 to 10 cm and a length of about 1 to 50 cm).

Although such a commercially available sponge is preferred, similar sponges having substantially the same desired characteristics could also be used and/or manufactured. For instance, a tridimensional PVA-derived support structure may be manufactured by cross-linking PVA molecules with bi-functional agents such as epichlorohydrin, as described in US patent No 5,456,921 or with other agents such as 2,3 dibromopropanol, sodium trimetaphosphate, phosphorous oxichloride, linear anhydrides of di-carboxylic acids, diepoxides, dialdehydes, phosgene, imidazolium salts of polycarboxylic acids, cyanuril chloride and derivatives thereof.

In a more preferred embodiment, the support structure consists essentially of cross-linked polyvinylalcohol (PVA) molecules, including but not limited to amino-ethyl-polyvinylalcohol (AE-PVA), arginyl-glycyl-aspartyl- polyvinylalcohol (RGD-PVA) and derivatives thereof. Such cross-linked polyvinylalcohol (PVA) molecules may be obtained by polymer treatment with a cross-linking agent such as epichlorohydrin, 2,3-dibromopropanol, sodium trimetaphosphate, formaldehyde, glutaraldehyde and other functional aldehydes. Preferably, the cross-linking degree of the support structure is adjusted between about 1% to 10% since it is known that high cross-linking generates a reduction of chain flexibility which is required for hydrogen association. However, for other types of materials, the cross-linking degree may be of up to 50%. Once a tridimensional support structure having desired selected features has been synthesized, it is preferably washed and sterilized before use.

As mentioned previously, the support structure of the invention may also be enriched with various types of bioactive molecules in order to optimize and/or increase cell-matrix interactions, cell-cell interactions and matrix-recipient

interactions and/or to improve the cells attachment and/or cells proliferating capabilities of the structure.

A non-restrictive list of examples of interesting bioactive molecules includes:

- 5 - signaling molecules and extracellular biocompatible matrix proteins (e.g., fibronectin, laminine) or motifs of these proteins such as peptides where the RGD sequence (Arg-Gly-Asp) is present;
- peptide binding motifs of receptors involved in cell-cell interactions (e.g. integrines, cadherines);
- 10 - carbohydrates or carbohydrate derivatives such as glycosaminoglycans (heparin, heparan sulfate), N-glycans, sialic and polysialic acid, sialyl sugars, carbohydrate dendrimers, sulfated glycoconjugates; and
- growth factors or hormones or active components of such signaling molecules (e.g. EGF, HGF).

15 Methods for linking bioactive molecules to PVA or equivalent polymers are numerous. Examples are as follows:

a) Methods to link peptides directly to a polyhydroxylic polymer:

- polymer activation with cyanogen bromide (BrCN) and peptide binding via amino groups;
- 20 - polymer activation with p-benzoquinone and peptide binding via amino groups;
- polymer reaction with trichloro-S-triazine (cyanuric chloride) and peptide binding via amino groups;

b) Methods to link peptides on polymeric matrices derivatized with carboxyl functions:

25 Support structure exhibiting carboxyl groups can be obtained by derivatization with carboxyalkyl groups, following treatment with  $\epsilon$ -chloroalkyl carboxylic acids  $X-(CH_2)_n-COOH$  where:  $X = Cl, Br, I$  and  $n = 1-12$  and more. As an example (not limitative), carboxymethyl (CM)-PVA structures obtained by

30 treatment of PVA with monochloroacetic acid can be considered. The carboxylic functions can be involved in:

- reactions with carbodiimides and amino groups of peptides;

- reaction with  $\text{SOCl}_2$  and amino groups of peptides;
- reaction with Woodward reagent (activation of carboxyl functions with N-ethyl-5-phenylisoxazolium3'-sulfonate) and peptide binding via amino groups;
- 5      - reaction with azide (treatment of CM-matrices with hydrazine and then with  $\text{NaNO}_2$ ) and peptide binding via amino groups.

c) Methods to link peptides to polymeric matrices derivatized with amino functions:

Support structure can be obtained by derivatization with aminoalkyl groups, following treatment with  $\text{X}-(\text{CH}_2)_n-\text{NH}_2$  where:  $\text{X} = \text{Cl, Br, I}$  and  $n = 1-12$  and more. As an example (not limitative), can be considered the aminoethyl (AE)-PVA matrices obtained by PVA treatment with chloroethylamine. The amino group can be involved in:

- reaction with carbodiimide and peptide binding via carboxyl groups;
- 15      - reaction with dialdehydes (i.e. glutaraldehyde) and peptide binding via amino groups (with a Schiff base as intermediate);
- reaction with  $\text{COCl}_2$  (carbonyl dichloride) and peptide binding via amino groups.

d) Methods to link peptides to polymeric matrices derivatized with thiol (SH) functions:

Polymeric matrices can be obtained by derivatization with thioalkyl groups, following treatment with  $\text{X}-(\text{CH}_2)_n-\text{SH}$  where:  $\text{X} = \text{Cl, Br, I}$  and  $n = 1-12$  and more. As an example (not limitative), can be considered the thiopropyl (SH)-PVA matrices obtained by PVA treatment with chloropropylthiol. The thiol function can be involved in reaction of HS-PVA with 2,2'-dipyridyl disulfide; the PVA-S-pyridyl disulfide obtained will bind Cys-peptides (i.e., CRGD) via their HS-(Cys) groups.

Methods to obtain a controlled release of active agents (i.e. specific peptides modulating cell adhesion, growth factors, etc.) from the support structure (or matrix) of the invention can also be envisaged. It could be possible for instance to load a PVA-derivatized matrix according to the invention with selected active agents by swelling the PVA matrix in the presence of selected active agent(s), then drying the PVA-gel obtained. When cell culture is initiated, the

active agent would preferably be released by diffusion through the matrix or by controlled lysis of specific links. It may be also desirable to allow a bio-erosion of the matrix over the cell-culturing period by conjugating together the active agent and the polymers of the matrix with hydrolyzable bonds. Such bonds may be: esters, amidic functions, particular carbohydrate linkages, and the like.

### **C) Uses of the tridimensional support structure of the invention**

The biocompatible support structure of the present invention has many applications for instance in sutures, in drug delivery systems (e.g. microencapsulated islet of Langerhans for the treatment of diabetes), in tissue engineering (e.g. implants, cartilage replacement, artificial skin, nerve reconstruction), in artificial cells (e.g. red-blood-cell substitutes), as a bioartificial organ (e.g. liver, kidney, pancreas), in gene therapy (encapsulation of genetically modified cells), and in *ex vivo* methods for producing therapeutic proteins, for the detoxification of body fluids, and for evaluating the toxicity and biological activity of compounds in the pharmaceutical industry.

#### **C-1) Bioartificial organ**

According to another aspect, the invention relates to a bioartificial organ, comprising: i) a biocompatible support structure as defined previously, and ii) living cells which are adhered and which are proliferating on the support structure. As used herein, the term "bioartificial organ" include also "bioreactor".

Bioartificial organs and/or bioreactors incorporating the matrix of the invention could be particularly useful for: transplantation purposes (e.g. hepatocyte transplantation, liver regeneration), the production of prosthesis, the production of therapeutic proteins, *ex vivo* body fluids detoxification, or testing new pharmaceutical compounds.

Preferably, the bioartificial organ consists of a bioartificial liver, a bioartificial kidney or of a bioartificial pancreas. According to a most preferred embodiment, the bioartificial organ consists of a bioartificial liver comprising from about 1 million to about 50 million hepatocytes/cm<sup>3</sup> (more preferably about 25 to 30 million/cm<sup>3</sup>) attached and proliferating onto a support structure made of PVA.

As it will be explained with more details hereinafter, the bioartificial organ of the invention may be used for carrying out the following methods:

- a method for culturing cells in three dimensions *in vitro*;
- a method for producing therapeutic proteins *in vitro*;
- 5 - a method for detoxifying biological fluids *ex vivo*;
- a method for assaying *in vitro* the toxicity, biological activity or pharmaceutical activity of drugs; and
- a method for prolonging the life of a patient in need of an organ transplantation.

10 More particularly, a bioartificial liver according to the invention has numerous applications such as:

- production of therapeutic proteins normally synthesized by the liver (e.g. albumin, ceruloplasmin, and clotting factors);
- use as an *ex vivo* detoxification device for patients suffering acute intoxication
- 15 with drugs or toxins;
- use as an *in vitro* tool in predictive toxicology for early pre-clinical evaluation and optimization of lead compounds in the pharmaceutical industry (predictive toxicology or drug metabolism); and
- use as bioartificial liver in acute liver failure for bridging with transplantation.

20 Therefore, according to another related aspect, the invention relates to a method for prolonging the life of a mammal. The method comprises the steps of providing a bioartificial organ as defined previously, and introducing this bioartificial organ in the body of a mammal in need thereof in replacement of a malfunctioning organ. Preferably, bioartificial organ is a bioartificial liver, a

25 bioartificial kidney or a bioartificial pancreas.

According to another related aspect, the invention relates to a method for manufacturing a bioartificial organ comprising a plurality of cells. The method comprises the steps of:

- isolating desired cells from a mammal;
- 30 - introducing these cells into a suitable aqueous culture system comprising (i) a suitable culture medium for the *in vitro* or *ex vivo* culture of said cells, and (ii) a biocompatible support structure as previously; and



- generating a suitable flow of the culture medium and of the cells through the biocompatible support structure for a sufficient period of time and under conditions for allowing cells to adhere to the biocompatible support structure and replicate therein. The circulation of culture media is preferably continuous, but is may also be pulsed.

C-2) Method, device and system for cells culture

According to a further aspect, the invention relates to a method for culturing cells. The method comprises the steps of:

- providing a suitable aqueous culture system comprising: (i) a suitable culture medium, (ii) a biocompatible support structure as defined previously, and (iii) cells for which culture is desired;
- generating a suitable flow of the culture medium and of the cells through the biocompatible support structure for a sufficient period of time and under conditions for allowing cells to adhere to the biocompatible support structure and replicate therein; and, optionally
- recovering in the flow of culture medium, molecules produced by the cells.

Preferably, the cells consist of hepatocytes, cardiomyocytes, fibroblasts, osteoblasts, cancer cells, monoclonal cells, kidney cells, and pancreatic cells. Therefore, recovered molecules produced by the cells may be human therapeutic proteins (e.g. albumin, ceruloplasmin, insulin, clotting factors, growth factors, monoclonal antibodies, hepatic enzymes, pancreatic enzymes and intestinal enzymes. Of course, the cells may be genetically modified in order to produce such human therapeutic proteins or in order to increase a basal level of secretion.

According to a related aspect, the invention relates to a device for culturing cells in three dimensions. A preferred embodiment of a culture system comprising such a device is shown at Figure 2. More particularly, the device (1) comprises a cylindrical waterproof housing (3) through which a culture medium (5) can circulate. The housing (3) has an inlet (7) and an outlet (9) capable of a waterproof connection to pumping means (11). The device (1) also comprises a biocompatible support structure (2) as defined previously that is enclosed into the waterproof housing (3).

According to another related aspect, the invention relates to a tridimensional system for cell culture and tissue growing. A preferred embodiment of a culture system according to the invention is shown at Figure 2. The tridimensional cell culture system (20) of the invention comprises:

- 5 - cells (not shown) for which culture in three-dimension is desired;
- a culture medium (5) that is suitable for the *in vitro* or *ex vivo* culture of the cells;
- a cell culture device (1), as defined previously, for culturing the cells; and
- pumping means (11) for circulating the culture medium through the cell culture  
10 device (1).

Preferably, the pumping means (11) have control means to adjust a flow of culture medium circulating through the device and through the biocompatible support structure. The circulation of culture media is preferably continuous, but it may also be pulsed.

- 15 More preferably, the tridimensional cell culture system (20) further comprises an oxygenator (15) for injecting oxygen in the system (preferably 95% O<sub>2</sub> and 5% CO<sub>2</sub>). Preferably also, the system (20) further comprises a reservoir (15) filled with culture media (5) for insuring a minimum level of media in the system. The cell culture device (1), the oxygenator (15), the pumping means  
20 (11), the reservoir (15) are connected with biocompatible tubes (4).

- According to a preferred embodiment, the support structure is put in a suitable culture medium and under suitable culture conditions with the cells to be cultured. Preferably, the cells and the support structure are put in a dynamic cell culture system which allows a continuous flow of medium through the matrix and  
25 cells are seeded in sufficient quantities so that proper cell-cell contacts are established. The culture system to be used must allow physiological exchanges between the cells and the extracellular fluid. It is also highly preferable that the composition and the circulation of the medium through the cellular compartments be carefully controlled. Well-known culture systems and bioreactors which have  
30 been used in various studies on cell physiology, metabolism and morphology, in pharmacology and toxicology, as well as in the development of bioartificial organs include: BAL™ device, Hollow Fiber Bioreactor, CELLMAX FLOW MODULE™,

rotating-wall vessels (RWV), Flat Membrane bioreactor (FMB). In all these systems, optimal culture conditions (pH, %CO<sub>2</sub>, %O<sub>2</sub>, T°) may be maintained for long periods of time.

According to a preferred embodiment of the invention, the dynamic cell culture system comprises a CELLMAX FLOW MODULE™ (CELLCO™, Spectrum Laboratories Inc., Laguna Hills, USA) that has been adapted, by the present inventors, to be used with the matrix of the invention. More particularly, a cylindrical glass cartridge of 5.1 cm in length and 2.1 cm in diameter was designed to fit the PVA sponges. Once in culture the cells attach gradually to the matrix, and after a certain period of time, they typically colonize most of the internal and external surfaces of the matrix. Depending on the desired uses, the culture period should last such that the matrix entraps an adequate number of cells, preferably from about 1 million to 25 million of cells/cm<sup>3</sup>.

#### C-3) Ex vivo method for detoxification of blood

According to another related aspect, the invention relates to a method for detoxifying ex vivo blood of a mammal from undesirable chemicals or toxins such as acetaminophene, metronizadol, antitumoral agents (e.g. methotrexate, mercaptopurine), poisons (e.g. acetone, chloroform), drugs (e.g. cocaine, heroine) etc. The method comprises the steps of:

- providing a bioartificial organ, preferably bioartificial liver, as defined previously, the bioartificial comprising cells with detoxifying capabilities;
- circulating through the bioartificial organ blood of the mammal under ex vivo conditions such that the cells of the bioartificial organ detoxicate circulating blood from undesirable drugs or toxins.

#### C-4) Method for in vitro assessment of toxicity, biological activity, and/or pharmacological activity of a compound

According to another related aspect, the invention relates to a method for assaying in vitro the toxicity, biological activity, and/or pharmacological activity of various compounds such as known or potential pharmaceutical compounds, carcinogenic compounds, toxic compounds (e.g. toxins, solvents), carcinogenic

compounds, drugs (e.g. cocaine, heroine) etc. The method comprises the steps of:

- providing a compound, of a plurality of compounds, for which assessment of toxicity or biological activity is desired;
- 5 - providing a bioartificial organ as defined previously, the organ comprising cells for which compound(s) assessment is desired;
- contacting the compound(s) with the bioartificial organ;
- optionally circulating through the bioartificial organ a suitable culture medium for the *in vitro* or *ex vivo* culture of the cells; and
- 10 - evaluating the toxicity, biological activity, and/or pharmacological activity of the compound(s) on the cells of the bioartificial organ.

A non-restrictive list of suitable cells useful for carrying out the method of the invention includes hepatocytes, cardiomyocytes, fibroblasts, osteoblasts, cancer cells, monoclonal cells, kidney cells, and pancreatic cells.

15 The toxicity, biological activity, and/or pharmacological activity of the compound(s) may be done using well-known methods, techniques or tools. For instance, one may easily measure intracellular or secreted levels of proteins (e.g. albumin or lactate dehydrogenase released by hepatocytes), cell survival, mortality and/or functions.

20

### EXAMPLES

As a proof of concept, hepatocytes were inoculated on modified or unmodified polymer PVA matrices. The results obtained and shown hereinafter clearly indicate that PVA-derived matrices have a great potential for the  
25 tridimensional culture of cells. Indeed, it was observed that polymers treated with 2-chloroethylamine hydrochloride and having ethylamine functions in their chemical composition demonstrate an increased adherence of hepatocytes on their surfaces.

30 It is to be understood however that the following examples are illustrative of the wide range of applicability of the present invention and are not intended to limit its scope. Modifications and variations can be made therein without departing from the spirit and scope of the invention. Although any methods and

materials similar or equivalent to those described herein can be used in practice for testing of the present invention, the preferred methods and materials are described.

## 5 **A) Introduction**

The liver performs numerous complex functions. It is involved in the metabolism of carbohydrates, lipids, amino acids and proteins. It is responsible for glycogenolysis and gluconeogenesis, the synthesis of lipoproteins and cholesterol, and the synthesis of essential proteins such as albumin, transferrin and clotting factors. The liver plays a prominent role in the biotransformation of xenobiotics and in detoxification processes. It is the site of bile production and the storage of essential nutrients including retinol, folic acid and cobalamin. Failure of the liver to carry out its normal functions as a result of liver disease leads to a life-threatening condition.

Death by liver disease occurs mainly in two clinical settings: cirrhosis and fulminant hepatic failure (FHF). Cirrhosis is the end stage of liver disease characterized by the replacement of normal tissue with fibrotic tissue, culminating in the confinement of the remaining hepatocytes, which no longer have the capacity to regenerate. Cirrhosis develops in alcoholism and chronic hepatitis. FHF is an extremely severe disease with a mortality rate of more than 80%. Its major cause is hepatitis following chemical intoxication or viral infection. Because the onset of FHF is sudden and its progression very rapid, death can occur within only a few weeks after the symptoms have appeared. Liver dysfunction is accompanied by increased serum liver enzymes, ammonia and bilirubin, as well as by decreased serum albumin and clotting factors. Ultimately, encephalopathy sets in, but the exact mechanisms responsible for this complication are still unknown.

Liver disease is a worldwide major problem. In North America, over 20 millions people are stricken by liver disease, which leads to the death of more than 40 000 individuals each year. Liver cirrhosis is the seventh leading cause of death by disease, affecting several hundred million people around the world. In the United States, hepatitis C virus (HCV)-related liver disease is the single most

common cause for liver transplantation. In Canada, increased incidence of liver disease due to viral infection is anticipated, as it is estimated that at least 1% of the population is infected with HCV, a figure that clearly shows endemic proportions. The country that is hardest hit by HCV is Egypt, where it has been  
5 evaluated that roughly 24% of the population carries HCV.

The management of liver failure represents a formidable therapeutic challenge. Liver transplantation appears to be the long-term solution. In spite of this, there is a severe lack of well-preserved livers available for transplantation. In 1996 in the United States, 4 058 liver transplant operations were performed, but it  
10 has been estimated that up to 10 000 potential recipients died because of organ scarcity. The deficit in liver availability has become more pronounced in the last 10 years. In the United States, from 1988 to 1996, the number of liver donors increased 2.4-fold, while the number of patients on the waiting list for a transplant soared from 616 to 7467 (over 10 fold), and the number of deaths resulting from  
15 lack of proper treatment quintupled.

In view of the unavailability of organs at the critical stage of liver failure, there is an urgent need to develop systems which could provide "bridging" support to the patient awaiting a donor organ, thus significantly increasing chances of survival. Procedures bypassing the necessity of transplantation  
20 altogether might also even be possible. At the present time, efforts are being devoted to designing artificial liver tissue/organ systems in order to find a viable solution to end-stage liver disease therapy. The objective of providing bioartificial liver therapy requires that these systems be engineered so that the hepatocytes function properly, and therefore, provide the capacity to save the life of a patient  
25 undergoing liver failure.

The microenvironment of the cells in a bioartificial organ is of prime importance for expression of their specific functions. For hepatocytes, there is a close relationship between the tridimensional architecture of the cells and their differentiation. Morphological integrity and intercellular communication are  
30 associated with the proper biochemical regulation of hepatocytes. Optimal conditions for the culture of hepatocytes require that the tri-dimensional organization of the cells *in vitro* mimic the organization seen *in vivo* as closely as

possible. In an *in vitro* culture system for hepatocytes, the topography of the tridimensional substrate can have its own effects on the cells, influencing cellular polarization, cytoskeletal arrangement and functional activity. In addition to the information generated by the physical microenvironment, biochemical components of the milieu are of key importance in producing signals that promote cell differentiation and function.

We are now proposing new polymeric materials based on the cross-linking of polyvinylalcohol (PVA), followed by its derivatization with specific alkyl-amino and/or peptide groups. These materials with higher compatibility can be particularly useful as matrices for cells and tissues growing for bioartificial livers and other organs. These polymeric materials were of interest, having stable mechanical and chemical properties that could be useful for further surface modifications. Considering that the number of cell-cell and cell-matrix interactions is very important in maintaining differentiation, liver-specific functions and hepatocyte viability, the characteristics of that polymer were tested in order to determine whether a polymeric PVA sponge and other similar materials could be optimized for providing a suitable microenvironment for the tridimensional culture of hepatocytes.

The PVA matrix of the invention shows better mechanical properties since this polymer can be stabilized by: i) covalent cross-linking and ii) via hydrogen bonding. PVA chains are known to be easily stabilized by hydrogen bonds (with calculated length of 4.5 - 5.7 Å and confirmed by X-ray measurement). Only a proper modification of PVA can ensure proper mechanical properties. For instance, only a moderately low density of covalent epichlorohydrin cross-linking bridges (calculated at 8.4 Å) allows enough flexibility of the chains to induce their self-assembly by hydrogen bonds (4.5 Å). This is why PVA exhibits interesting particular properties, related to the degree of cross-linking.

### **B) Mat rial and methods**

#### ***Preparation of collagen coated dishes***

Type I collagen was obtained from rat tail tendon by the procedure of Michalopoulos and Pitot (*Exp Cell Res.* 94: 70-78, 1975). Plates were prepared

by distributing 1.5 ml of the collagen solution (approximately 0.75 mg/60 mm tissue culture dishes); they were then kept overnight in a sterile atmosphere.

#### *Isolation and culture of rat hepatocytes*

5        Hepatocytes were isolated from male Sprague Dawley rats (150-300 g) by a modification of the collagenase perfusion technique of Seglen (*Meth Cell Biol.* 13: 29-83, 1976) as described in Guillemette *et al.* (*Biochem Cell Biol* 71: 7-13, 1993). Briefly, the liver was first perfused via the portal vein with 400 ml of a calcium-free Hanks' buffer solution supplemented with 0.25 mM of EGTA for 15  
10 minutes and then perfused with a second Hanks' buffer solution containing 100-200 U/ml of collagenase (Sigma-Aldrich) with 5 mM of calcium hydrochloride for 8 minutes to digest the liver tissue. The perfusates were equilibrated with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. Then the perfused liver was resected and settled in a glass dish containing cold Williams Medium E (WME, Sigma-Aldrich) + 10% bovine fetal  
15 serum (FBS) (Gibco Life Technologies) fresh medium. Then the capsule was slowly teased apart and the lobes were delicately shaken to recover the hepatocytes. The resulting suspension was filtered through two nylon meshes with grid sizes of 250 µm and 50 µm. The cell pellet was collected by centrifugation at 50 g for 2 minutes. Viable hepatocytes were isolated from  
20 cellular debris and non-parenchymal liver cells using a Percoll™ (Amersham Pharmacia Biotech) gradient centrifugation at 4°C at 1000 g for 8 minutes. The cell pellet was washed once with WME + 10% FBS. Hepatocyte viability was determined by flow cytometry (FACSCAN™, Becton Dickinson) with propidium iodide (2 mg/ml). To examine how hepatocytes function on the PVA polymer  
25 support, we performed measurements of liver-specific functions.

#### *Culture conditions*

PVA-matrices in static conditions were placed in 60 mm culture Petri dishes to which 5 ml of culture medium was added. A modified cartridge housing  
30 the polymer was secured vertically to the CELLMAX FLOW MODULE™ (CELLCO™, Spectrum Laboratories Inc., Laguna Hills, USA) for the constructs in flow conditions. It was exposed to a 5 ml/min (lowest speed of the module)



continuous flow of L-15 (Leibovit'z L-15 ) culture medium (*Meth Cell Biol.* 13: 29-83, 1976) pumped from a 100 ml reservoir (total volume of medium was 60 ml) and recirculated back to the reservoir after passing through the module (See Figure 2). The flow module and the cartridge were placed in an incubator and  
5 cultures were performed at 37°C with 5% CO<sub>2</sub>. The media was changed every day for both the static and dynamic cultures.

#### *Polymer seeding*

Constructs (PVA-discs fitting to 60 mm petri dishes) under static culture  
10 conditions were seeded with  $2 \times 10^6$  hepatocytes/disc. Constructs (PVA-cylinder shape 1.5 cm in diameter and 2.0 cm high) under dynamic culture conditions were seeded with  $3.0 \times 10^7$  hepatocytes/cylinder by injection inoculation.

#### *Aminoethylation of PVA-matrices*

15 Polyvinylalcohol (PVA) sponges were purchased from PVA Unlimited Company (Warsaw, Indiana, USA). The surface modifications were done as follows. Sponges were dried for 48 hours in an oven at 40°C. Then the dry weight of sponges to be modified was determined. The sponges were then hydrated and covered with a minimum of water at 70°C. Everything was placed in a 70°C  
20 water-bath. An amount of 2-chloroethylamine hydrochloride (Fluka Chemika-Biochemika) equal to the weight of the polymer material was dissolved in a minimum of water and added to the sponges minimal volumes of 10 M NaOH were added to keep the reactional medium at pH = 9.0 for a 2-hour reaction time. Finally, the modified sponges were washed five times in distilled water and dried  
25 for 48 hours at 40°C.

#### *Determination of the albumin secretion of hepatocytes cultured under different conditions*

Every day, the culture medium was collected from the different systems in  
30 Eppendorf tubes and kept at -20°C until assayed. The rate of albumin secretion from the hepatocytes was quantified by a sandwich enzyme-linked immunosorbent assay (ELISA) using rat-specific antibodies. Briefly, 96-well

plates (FALCON™, Becton Dickinson) were coated (200 µl/well) with 1 µg/mL of anti-rat albumin antibody (Nordic Cederlane Laboratories) diluted with 0.1 M Na<sub>2</sub>CO<sub>3</sub> buffer solution, pH = 9.6 and left overnight at 4°C. After washing the plates three times with a phosphate buffer saline (PBS)/0.05% FBS (Gibco Life Technologies) (200 µl/well) for 30 minutes at 37°C, the plates were blocked with a PBS/0.05% FBS (Gibco Life Technologies) solution for 30 minutes at 37°C. After three washes with the PBS buffer solution, pH=7.3, 200 µl of the diluted (dilution solution: PBS/0.05% TWEEN™/0.5% bovine serum albumin (BSA, previously shown not to give any cross-reaction with rat anti-albumin antibodies used for ELISA), Sigma-Aldrich, ICN Biomedicals) samples and standards (chromatographically purified albumin, Sigma-Aldrich) was deposited in triplicate on the plates and incubated for 1 hour at 37°C. After three washings with a PBS/0.05% TWEEN™ solution pH = 7.3, peroxidase-conjugated anti-rat albumin antibody (1 µg/ ml) diluted in PBS/5% FBS solution was added and incubated for 1 hour at 37°C. After three washings with PBS-0.05% TWEEN™ solution, 200 µl of substrate (0.5 mg/ml o-phenylenediamine, Sigma-Aldrich) diluted in 0.1M phosphate citrate buffer pH=5 with 0.006% H<sub>2</sub>O<sub>2</sub> was added to each well, and the optical density at 490 nm was measured with a microplate TITERTEK MULTISKAN™ reader.

#### *Viability determination of hepatocytes*

Lactate dehydrogenase (LDH) activity was determined in the media as a measure of hepatocyte deterioration. For this study, the culture medium was harvested daily and the 24-hour release of LDH into the medium was quantitated. Total LDH levels in the cells were also determined for each culture. For the LDH assay, 28 µl of the sample was added to each well on a 96-well plate. To obtain the value representing 100% LDH release, cells were treated with 1% Triton 10X for 10 minutes. Then 250 µl of the reagent for LDH assay (0.12 M NaCl, 4.83 mM KCl, 0.96 mM KH<sub>2</sub>PO<sub>4</sub>, 1.96 mM MgSO<sub>4</sub>·7H<sub>2</sub>O, 2.5 mM CaCl<sub>2</sub>·2H<sub>2</sub>O, 23.8 mM NaHCO<sub>3</sub>, 2% BSA, 6.8 mM Na pyruvate, 1 mM NADH, pH= 7.4) was added to each well and the optical density was immediately read at 340 nm with a

microplate TITERTEK MULTISKAN™ reader. All measurements were done in triplicate.

*Determination of cellular adherence to different matrices*

5        The cellular adhesion on the supports was determined by counting the number of cells recovered in the culture medium. For the initial count, after the adherence period, the cells were counted as follows: Number of inoculated cells – Number of cells found in the medium = Number of cells that remained attached to the substratum.

10       Thereafter, cells were counted daily as follows: Number of cells that remained attached to the substratum at the previous day - Number of cells found in the medium = Number of cells that remained attached to the substratum at the day of measurement.

15    **C) Results**

**Example 1: Preliminary trials on bidimensional cultures**

Table 1 hereinafter shows best adhesion properties for aminoethyl derivatives of different polymers studied.

**Table 1: Composition, mechanical and cell adhesion properties of different polymeric films and derivatives used as possible matrices for hepatocytes culture.**

Films and chemical compositions	Mechanical stability	Adhesion property
CM-CLA (6)-CLPVA-6	+	+
CMCL6-CLPVA6 +.5% collagen	+	+
CL (A-PVA)6	-	Nd
CL (A-PVA)6 + 5% collagen	-	Nd
AECLA/PropylCLA/CMCLA6 1/1/1 + 2% epi	+	++
CMCLA6+CLPVA3/1+2% epi + 5% collagen	+	Nd
AECLA/ PropylCLA/CMCLA6 1/1/1	+	++
Agar	+++	-
1/3 AECLA-0/Agar	+++	+
1/2 AECLA-0/Agar	+++	Nd
3/2 AECLA-0/Agar	+++	Nd
AECLA-0	+/-	+++
AECLA-6	+/-	+++
1% agarose	+++	-
1% agarose + 1/3 AECLA-0	+++	++
1% agarose + 1/2 AECLA-0	+++	++
1% agarose + 2/1 AECLA-0	+++	Nd
Chitosan + 5% collagen	+	++

**Legend :** +++ = excellent, ++ = good, + = low, +/- = unstable, -= none, Nd=not defined.

**Abbreviations:** CM, CarboxyMethyl; PVA, polyvinylalcohol; AE, aminoethyl; epi, epichlorohydrine (cross-linking agent); CLA, cross-linked amylose n (0-6) = cross-linking degree, defined as the amount of cross-linking agent (g) used to cross-link 100g of polymer.

#### **Example 2: Tridimensional hepatocytes culture on PVA-polymer support under static conditions**

Figure 3 shows better maintenance of cell adhesion on PVA and AE-PVA matrices as compared to collagen film.

Table 2 shows higher albumin secretion with AE-PVA as compared to collagen film.

Figure 4 shows stabilization of cell viability with PVA matrices after 72h in culture.

**Table 2: Metabolic activity of hepatocytes under static culture conditions.**

5	Albumin secretion ( $\mu\text{g}/10^6$ cells/24 h)					Activity retention	
	Time (hrs)					%	
	24	48	72	96	120		
10	F	26.3	19.2	12.8	4.8	2.3	8.6
	M	28.8	20.3	8.0	12.3	4.1	14.2
	MM	27.5	25.1	12.4	9.4	4.9	17.8

**Abbreviations:** *M*, disc of PVA-matrix unmodified; *MM*, disc on PVA-matrix modified by aminoethylation both being tridimensional static cultures; and *F*, collagen film in monolayer culture.

**Example 3: Tridimensional hepatocytes culture on PVA-polymer support under dynamic conditions**

Figure 5 shows better maintenance of cell adhesion on PVA and AE-PVA matrices under constant perfusion.

Table 4 shows higher albumin production with PVA and AE-PVA matrices under perfusion conditions as compared to collagen film (cf. Table 2).

Figure 6 shows stabilization of cell viability with PVA matrices after 72h in culture under perfusion conditions.

**Table 4: Metabolic activity of hepatocytes in dynamic culture conditions.**

30		<u>Albumin secretion (<math>\mu\text{g}/10^6</math> cells/24 h)</u>					Activity retention
		Time (hrs)					
35		24	48	72	96	120	%
	cM	28.7	16.2	7.8	9.1	7.2	25.2
40	cMM	27.8	18.8	12.8	12.3	6.1	22.0

**Abbreviations:** *cM*, cylinder-shaped PVA polymer-matrix without any modification; and *cMM*, cylinder-shaped PVA polymer-matrix modified with aminoethylation, both being tridimensional supports under dynamic culture conditions.

#### D) Discussion

Hepatocytes were seeded under two different culture conditions: 1) in a static system, on collagen film (F) or on a PVA synthetic polymer disc (M), or on a PVA-aminoethyl modified polymer disc (MM); 2) in a dynamic system: on a PVA synthetic polymer cylinder-shaped matrix (cM) or on PVA-aminoethyl modified polymer cylinder-shaped matrix (cMM).

The quantification of albumin secretion (Tables 2 and 4) showed that hepatocytes cultured under dynamic conditions retained a superior percentage of secretion activity after 120 hours, relative to day 1, than hepatocytes cultured under static conditions. Moreover, hepatocytes cultured on tridimensional supports under dynamic or static conditions showed a better final retention of albumin secretion function (relative to initial activity at day 1) compared to hepatocytes seeded on bidimensional monolayer culture support.

Figures 4 and 6 show the percentage of LDH release in the culture medium as a measure of loss of hepatocyte viability in culture. We observed that cultures on collagen film show higher quantities of free LDH than cultures where hepatocytes were seeded on PVA-polymer matrices.

The results in Figures 3 and 5 indicate that the number of adherent cells on the collagen film decreases rapidly with time. In contrast, the number of hepatocytes seeded on the PVA-polymer matrices is almost stable over time, showing the efficiency of cell adhesion on a tridimensional microenvironment. This support is more adapted to maintaining the seeded hepatocytes because there are more interactions between the matrix and the cultured cells.

In summary, these results confirm that tridimensional polymers offer a better extracellular matrix environment for the adhesion of hepatocytes. Also, the results confirm that a perfusion system increases the beneficial properties of tridimensional culture: it maintains optimal conditions for the survival of hepatocytes and preserves albumin secretion activity.

While several embodiments of the invention have been described, it will be understood that the present invention is capable of further modifications, and this application is intended to cover any variations, uses, or adaptations of the invention, following in general the principles of the invention and including such

departures from the present disclosure as to come within knowledge or customary practice in the art to which the invention pertains, and as may be applied to the essential features hereinbefore set forth and falling within the scope of the invention or the limits of the appended claims.

CLAIMS:

1. A biocompatible support structure for culturing cells in three dimensions, the support structure consisting essentially of a biocompatible and non-  
5 biodegradable polymeric material on which cells may adhere and proliferate; said support structure forming, when saturated in a suitable aqueous medium, a porous tridimensional sponge-like scaffold with a plurality of interconnected pores, said pores being dimensioned and distributed so that a flow of at least  $0.1 \text{ ml/min}^{-1}\text{cm}^{-2}$  of an aqueous solution may circulate through said biocompatible  
10 support structure.
2. The biocompatible support structure of claim 1, wherein said pores are dimensioned and distributed so that a flow of at least  $0.5 \text{ ml/min}^{-1}\text{cm}^{-2}$  of an aqueous solution may circulate through the biocompatible support structure.  
15
3. The biocompatible support structure of claim 1 or 2, wherein said pores are dimensioned and distributed so that a flow of about 1 to about  $15 \text{ ml/min}^{-1}\text{cm}^{-2}$  of an aqueous solution may circulate through the biocompatible support structure.
- 20 4. The biocompatible support structure of any one of claims 1 to 3, wherein said pores have a diameter of about 100 to about  $1000 \mu\text{m}$ .
5. The biocompatible support structure of any one of claims 1 to 4, wherein it comprises from about 20 to about  $50 \text{ pores/cm}^2$ .  
25
6. The biocompatible support structure of any one of claims 1 to 5, wherein said biocompatible and non-biodegradable polymeric material is selected from the group consisting of polyvinylalcohol (PVA), polyuretans, polycyanoacrylates, polyhydroxyethyl methacrylate (PHEMA), methylmethacrylate (MMA), and N-vinyl  
30 pyrrolidone (N-VP).



7. The biocompatible support structure of any one of claims 1 to 6, wherein the polymeric material comprises an amine function.

8. The biocompatible support structure of any one of claims 1 to 6, wherein the support structure consists essentially of a polyhydroxylic polymer with alternate polar and non-polar groups.

9. The biocompatible support structure of claim 8, wherein the support structure consists essentially of cross-linked polyvinylalcohol (PVA) molecules.

10. The biocompatible support structure of claim 9, wherein the cross-linked polyvinylalcohol molecules are selected from the group consisting of amino-ethyl-polyvinylalcohol (AE-PVA), arginyl-glycyl-aspartyl-polyvinylalcohol (RGD-PVA) and derivatives thereof.

11. The biocompatible support structure of any one of claims 7 to 9, wherein the support structure consists essentially of polyvinylalcohol (PVA), and wherein said PVA comprises hydroxyl functions that have been modified with haloalkyl amines.

12. The biocompatible support structure of claim 11, wherein said haloalkyl amine is selected from the group consisting of 2-chloroethylamine hydrochloride, chloropropyl amine, bromoethylamine, iodoethylamine.

13. The biocompatible support structure of claim of any one of claims 1 to 11, wherein the support structure further comprises an associated polymer selected from the group consisting of polyethyleneglycol (PEG), agarose, starch, alginate, and chitosan.

14. The biocompatible support structure of any one of claims 1 to 13, wherein said support structure further comprises a bioactive molecule selected from the group consisting of: extracellular biocompatible support structure proteins, growth

factors, hormones, signaling molecules, peptide binding motifs of receptors, carbohydrates, and carbohydrates derivatives.

15. The biocompatible support structure of any one of claims 1 to 14, wherein  
5 said cells consist of mammalian cells.

16. The biocompatible support structure of claim 15, wherein said mammalian cells consist of human cells.

10 17. The biocompatible support structure of any one of claims 1 to 16, wherein said cells are selected from the group consisting of hepatocytes, cardiomyocytes, fibroblasts, osteoblasts, cancer cells, monoclonal cells, kidney cells, and pancreatic cells.

15 18. A bioartificial organ, comprising a biocompatible support structure as defined in any one of claims 1 to 17.

19. A bioartificial organ, comprising:

- 20 - a biocompatible support structure consisting essentially of a biocompatible polymeric material on which cells may adhere and proliferate, the support structure having the form of a porous tridimensional sponge-like scaffold with a plurality of interconnected pores, said pores being dimensioned and distributed so that a flow of at least  $0.1 \text{ ml/min}^{-1}\text{cm}^{-2}$  of an aqueous solution may circulate through said biocompatible support structure; and
- 25 - living cells which are adhered and which can proliferate on said support structure.

20. The bioartificial organ of claim 19, wherein said pores are dimensioned and distributed so that a flow of at least  $0.5 \text{ ml/min}^{-1}\text{cm}^{-2}$  of an aqueous solution  
30 may circulate through the biocompatible support structure.

21. The bioartificial organ of claim 19 or 20, wherein said pores are dimensioned and distributed so that a flow of about 1 to about 15 ml/min<sup>-1</sup>cm<sup>-2</sup> of an aqueous solution may circulate through the biocompatible support structure.

5 22. The bioartificial organ of any one of claims 19 to 21, wherein said pores have a diameter of about 100 to about 1000  $\mu$ m.

23. The bioartificial organ of any one of claims 19 to 22, wherein it comprises from about 20 to about 50 pores/cm<sup>2</sup>.

10

24. The bioartificial organ of any one of claims 19 to 23, wherein said biocompatible and non-biodegradable polymeric material is selected from the group consisting of polyvinylalcohol (PVA), polyuretans, polycyanoacrylates, polyhydroxyethyl methacrylate (PHEMA), methylmethacrylate (MMA), and N-vinyl  
15 pyrrolidone (N-VP).

25. The bioartificial organ of any one of claims 19 to 24, wherein the polymeric material comprises an amine function.

20 26. The bioartificial organ of any one of claims 19 to 25, wherein the support structure consists essentially of a polyhydroxylic polymer with alternate polar and non-polar groups.

27. The bioartificial organ of claim 26, wherein the support structure consists  
25 essentially of cross-linked polyvinylalcohol (PVA) molecules.

28. The bioartificial organ of claim 27, wherein the cross-linked polyvinylalcohol molecules are selected from the group consisting of amino-ethyl-polyvinylalcohol (AE-PVA), arginyl-glycyl-aspartyl- polyvinylalcohol (RGD-PVA)  
30 and derivatives thereof.

29. The bioartificial organ of any one of claims 26 to 28, wherein the support structure consists essentially of polyvinylalcohol (PVA), and wherein said PVA comprises hydroxyl functions that have been modified with haloalkyl amines.

5 30. The bioartificial organ of claim 29, wherein said haloalkyl amine is selected from the group consisting of 2-chloroethylamine hydrochloride, chloropropyl amine, bromoethylamine, iodoethylamine.

10 31. The bioartificial organ of claim of any one of claims 19 to 30, wherein the support structure further comprises an associated polymer selected from the group consisting of polyethyleneglycol (PEG), agarose, starch, alginate, and chitosan.

15 32. The bioartificial organ of any one of claims 19 to 31, wherein said support structure further comprises a bioactive molecule selected from the group consisting of: extracellular biocompatible support structure proteins, growth factors, hormones, signaling molecules, peptide binding motifs of receptors, carbohydrates, and carbohydrates derivatives.

20 33. The bioartificial organ of any one of claims 19 to 32, wherein said cells consist of mammalian cells.

25 34. The bioartificial organ of claim 33, wherein said mammalian cells consist of human cells.

35. The bioartificial organ of any one of claims 19 to 34, wherein said cells are selected from the group consisting of hepatocytes, cardiomyocytes, fibroblasts, osteoblasts, cancer cells, monoclonal cells, kidney cells, and pancreatic cells.

30 36. The bioartificial organ of any one of claims 19 to 35, wherein said bioartificial organ consists of a bioartificial liver, a bioartificial kidney and a bioartificial pancreas.

37. The bioartificial organ of any one of claims 19 to 36, for carrying out a method selected from the group consisting of:

- a method for culturing cells in three dimensions *in vitro*;
- 5 - a method for producing therapeutic proteins *in vitro*;
- a method for detoxifying biological fluids *ex vivo*;
- a method for assaying *in vitro* the toxicity, biological activity or pharmaceutical activity of drugs; and
- 10 - a method for prolonging the life of a patient in need of an organ transplantation.

38. A method for culturing cells, comprising:

- providing a suitable aqueous culture system comprising: i) a suitable culture medium, ii) a biocompatible support structure as defined in any one of claims 15 1 to 17, and iii) cells for which culture is desired;
- generating a suitable flow of said culture medium and of said cells through said biocompatible support structure for a sufficient period of time and under conditions for allowing cells to adhere to the biocompatible support structure and replicate therein.

20 39. The method of claim 38, further comprising the step of recovering in said flow of culture medium, molecules produced by said cells.

25 40. The method of claim 38 or 39, wherein said cells consist of cells genetically modified for producing a human therapeutic protein.

41. The method of any one of claims 39 to 40, wherein the molecules produced by said cells consist of human therapeutic proteins.

30 42. The method of claim 41, wherein said human therapeutic proteins are selected from the group consisting of albumin, ceruloplasmin, insulin, clotting

factors, growth factors, monoclonal antibodies, hepatic enzymes, pancreatic enzymes and intestinal enzymes.

43. The method of any one of claims 39 to 41, wherein said cells consists of  
5 hepatocytes, cardiomyocytes, fibroblasts, osteoblasts, cancer cells, monoclonal cells, kidney cells, and pancreatic cells.

44. A device for culturing cells comprising:

- a waterproof housing through which a culture medium can circulate, the  
10 housing having an inlet and an outlet capable of a waterproof connection to pumping means; and
- a biocompatible support structure as defined in any one of claims 1 to 17 that is enclosed into said waterproof housing.

15 45. A tridimensional cell culture system comprising:

- cells for which culture in three-dimension is desired;
- a culture medium that is suitable for the *in vitro* or *ex vivo* culture of said cells;
- a device for culturing cells as defined in claim 44; and
- pumping means for circulating a culture medium through said device.

20

46. The system of claim 45, wherein said cells are selected from the group consisting of hepatocytes, cardiomyocytes, fibroblasts, osteoblasts, cancer cells, monoclonal cells, kidney cells, and pancreatic cells.

25 47. A method for manufacturing a bioartificial organ comprising a plurality of cells, the method comprising the steps of:

- isolating said cells from a mammal;
- introducing said cells into a suitable aqueous culture system comprising:
  - i) a suitable culture medium for the *in vitro* or *ex vivo* culture of said cells,  
30 and
  - ii) a biocompatible support structure as defined in any one of claims 1 to 17;

and

- generating a suitable flow of said culture medium and of said cells through said biocompatible support structure for a sufficient period of time and under conditions for allowing cells to adhere to the biocompatible support structure and replicate therein.

5

48. A method for detoxifying *ex vivo* blood of a mammal from undesirable chemicals or toxins, the method comprising the steps of:

- providing a bioartificial organ as defined in any one of claims 19 to 36, said bioartificial comprising cells with detoxifying capabilities;
- 10 - circulating through said bioartificial organ blood of said mammal under *ex vivo* conditions which allows the cells of the bioartificial organ to detoxicate said blood from undesirable drugs or toxins.

15 49. The method of claim 48, wherein said chemical or toxin is selected from the group consisting of acetaminophene, metronidazol, antitumoral agents, poisons.

20 50. The method of claim 48 or 49, wherein the bioartificial organ consist of a bioartificial liver.

51. A method for prolonging the life of a mammal, comprising:

- providing a bioartificial organ as defined in any one of claims 19 to 36;
- introducing said bioartificial organ in the body of a mammal in need thereof in replacement of a malfunctioning organ.

25

52. The method of claim 51, wherein the bioartificial organ is selected from the group consisting of a bioartificial liver, a bioartificial kidney and a bioartificial pancreas.

30 53. A method for assaying *in vitro* the toxicity, biological activity, or pharmacological activity of a compound, comprising:

- providing a compound for which assessment of toxicity or biological activity is desired;
- providing a bioartificial organ as defined in any one of claims 19 to 36, said organ comprising cells for which said compound assessment is desired;
- 5 - contacting said compound with said bioartificial organ; and
- evaluating the toxicity, biological activity, or pharmacological activity of said compound on the cells of the bioartificial organ.

10 54. The method of claim 53, further comprising the step of circulating through said bioartificial organ a suitable culture medium for the *in vitro* or *ex vivo* culture of said cells.

15 55. The method of claim 53 or 54, wherein said compound is selected from the group consisting of drugs, pharmaceutical compounds, carcinogenic compounds, and toxic compounds.

20 56. The method of any one of claims 53 to 55, wherein the bioartificial organ comprises cells selected from the group consisting of hepatocytes, cardiomyocytes, fibroblasts, osteoblasts, cancer cells, monoclonal cells, kidney cells, and pancreatic cells.



1 / 4






FIG. 1



2 / 4



**FIG. 2**






FIGURE 3




FIGURE 4



4 / 4




FIGURE 5




FIGURE 6





## INTERNATIONAL SEARCH REPORT

ional Application No

PCT/CA 02/00652

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N5/06 A61L27/00 A61F2/02 C08L29/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61L A61F C08L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE MEDLINE 'Online!  July 1989 (1989-07)  MATSUDA T ET AL: "Development of a novel artificial matrix with cell adhesion peptides for cell culture and artificial and hybrid organs."  Database accession no. NLM2597562  XP002211622  abstract  &amp; ASAIO TRANSACTIONS / AMERICAN SOCIETY FOR ARTIFICIAL INTERNAL ORGANS. UNITED STATES 1989 JUL-SEP,  vol. 35, no. 3, July 1989 (1989-07), pages 677-679,  ISSN: 0889-7190</p> <p style="text-align: center;">--- -/-</p>	1-10, 13-28, 31-56

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the International filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

30 August 2002

Date of mailing of the international search report

16/09/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Didelon, F

## INTERNATIONAL SEARCH REPORT

onal Application No  
PCT/CA 02/00652

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 014, no. 096 (C-0692), 22 February 1990 (1990-02-22) & JP 01 305960 A (SANYO CHEM IND LTD), 11 December 1989 (1989-12-11) abstract	1-10, 13-28, 31-56
X	WO 00 44808 A (HUBBELL JEFFREY A ;SCHOENMAKERS RONALD (CH); ELBERT DONALD (CH); L) 3 August 2000 (2000-08-03) claims page 3, line 11 - line 20 page 52, line 1 -page 55, line 7	1-10, 13-28, 31-56
X	LIN HORNG-BAN ET AL: "Synthesis, surface, and cell-adhesion properties of polyurethanes containing covalently grafted RGD-peptides." JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, vol. 28, no. 3, 1994, pages 329-342, XP001098048 ISSN: 0021-9304 abstract figures 6,7 page 341, column 2, line 6-10	1-8, 13-24, 31-56
X	PAHERNIK S A ET AL: "High density culturing of porcine hepatocytes immobilized on nonwoven polyurethane-based biomatrices." CELLS TISSUES ORGANS, vol. 168, no. 3, 2001, pages 170-177, XP001095929 ISSN: 1422-6405 abstract page 171, column 2, paragraph 3 discussion	1-6, 13-24, 31-56
X	EP 0 470 681 A (GRACE W R & CO) 12 February 1992 (1992-02-12)  column 6, line 42 - line 57 claims	1-6, 13-24, 31-56
P,X	US 6 309 635 B1 (INGBER DONALD E ET AL) 30 October 2001 (2001-10-30)  results examples 3-5 column 3, line 36 -column 4, line 19 claims 1,7,10,15,16	1-6, 13-24, 31-56

# INTERNATIONAL SEARCH REPORT

national application No.  
PCT/CA 02/00652

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Pr test

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 1, 18, 19, 38, 44, 45, 47, 48, 51, 53 do not specify the nature of the possible polymers which are potentially able to form a porous scaffold on which cells can be cultured in three dimensions, but recite physical parameters linked to said scaffold. It appears therefore that a lack of clarity arises to such an extent as to render a complete search for the whole scope of said claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear, namely the polymers cited in claims 6-11.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## Information on patent family members

Original Application No

PCT/CA 02/00652

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 01305960	A	11-12-1989	NONE	
WO 0044808	A	03-08-2000	AU 3220400 A EP 1181323 A1 WO 0044808 A1	18-08-2000 27-02-2002 03-08-2000
EP 0470681	A	12-02-1992	EP 0470681 A2 JP 5168470 A CA 2048746 A1	12-02-1992 02-07-1993 09-02-1992
US 6309635	B1	30-10-2001	AT 152631 T CA 2121040 A1 DE 69219613 D1 DE 69219613 T2 EP 0610423 A1 JP 7508663 T JP 2002200162 A WO 9308850 A1 AT 139432 T DE 3751843 D1 DE 3751843 T2 EP 0299010 A1 JP 7102130 B JP 1501362 T WO 8803785 A1 US 5567612 A US 5804178 A US 5770193 A US 5759830 A US 5770417 A US 5041138 A US 5736372 A AT 119787 T AU 636346 B2 AU 5569190 A CA 2031532 A1 DE 69017820 D1 DE 69017820 T2 EP 0422209 A1 ES 2072434 T3 JP 10263070 A JP 4501080 T JP 3073766 B2 JP 2001314498 A WO 9012604 A1	15-05-1997 13-05-1993 12-06-1997 27-11-1997 17-08-1994 28-09-1995 16-07-2002 13-05-1993 15-07-1996 25-07-1996 12-12-1996 18-01-1989 08-11-1995 18-05-1989 02-06-1988 22-10-1996 08-09-1998 23-06-1998 02-06-1998 23-06-1998 20-08-1991 07-04-1998 15-04-1995 29-04-1993 16-11-1990 26-10-1990 20-04-1995 05-10-1995 17-04-1991 16-07-1995 06-10-1998 27-02-1992 07-08-2000 13-11-2001 01-11-1990

